Ketamine Queen Showdown Rocks Hollywood Court

A celebrity overdose case is now testing whether America’s justice system will punish dealers who profit from addiction—or accept a “time served” exit after a death.

Quick Take

Federal prosecutors are asking a judge to sentence Jasveen Sangha—dubbed the “Ketamine Queen”—to 15 years in prison for distributing ketamine resulting in Matthew Perry’s death.
Sangha has pleaded guilty to five federal charges; her defense is requesting time served after being in custody since August 2024.
Authorities say Sangha’s North Hollywood operation sold ketamine and other drugs in bulk, including sales tied to a separate 2019 overdose death.
The case highlights the uneasy line between legal ketamine therapy and an illicit supply chain that reached a high-profile Hollywood home.

Prosecutors Push 15 Years as Judge Weighs Sentencing

Federal prosecutors in the Central District of California have filed a sentencing memorandum urging a 15-year prison term for Jasveen Sangha, the North Hollywood woman widely referred to as the “Ketamine Queen.” Sangha pleaded guilty to five federal charges, including distribution of ketamine resulting in death, tied to actor Matthew Perry’s Oct. 28, 2023, overdose. Her attorneys are asking for time served, setting up a sharp dispute over punishment and deterrence.

From a law-and-order standpoint, prosecutors are emphasizing what they describe as a pattern: continuing to sell drugs even after learning that prior sales were linked to fatalities. The judge will decide the sentence, but the government’s position signals that “resulting in death” cases are not being treated as routine drug distribution. The public filing also underscores a broader enforcement priority—making upstream suppliers pay a steep price when someone dies.

How the Supply Chain Reached Matthew Perry’s Home

Investigators laid out a chain that, according to charging documents and plea records, ran from Sangha to intermediary Erik Fleming and then to Perry’s assistant, Kenneth Iwamasa. In October 2023, authorities say Sangha and Fleming sold 51 vials of ketamine to Iwamasa, who administered multiple injections to Perry. On the day Perry died at his Pacific Palisades home, prosecutors say Iwamasa gave three shots that proved fatal.

The case also includes allegations of cleanup after the fact. Authorities say that after Perry’s death, Sangha instructed Fleming via Signal to delete messages—an action prosecutors use to argue consciousness of guilt and a disregard for consequences. Sangha was arrested in August 2024 and has remained in federal custody since then. All five defendants connected to the case have pleaded guilty, avoiding a public trial but leaving sentencing as the next major decision point.

A Second Death and Claims of a High-Volume Operation

Prosecutors point to an earlier overdose death as a key reason the court should impose a long prison term. In August 2019, the government says Sangha sold four vials of ketamine to Cody McLaury, who died hours later from an overdose. The government alleges Sangha kept operating afterward, running a drug-involved premises in North Hollywood and distributing ketamine and methamphetamine. That history is central to the prosecution’s argument that leniency would fail to protect the public.

What This Means for Ketamine Therapy, Enforcement, and Public Trust

The case is unfolding amid wider public confusion about ketamine’s dual identity: a legitimate surgical anesthetic used in supervised settings, and a drug diverted into an illicit market. The research provided indicates Perry had pursued ketamine treatment for depression legally before seeking additional supply outside medical oversight. That distinction matters for policy: targeting illegal trafficking and careless prescribing is different from restricting legitimate care—yet high-profile deaths often trigger sweeping responses.

For conservatives who want both accountability and constitutional restraint, the practical takeaway is straightforward: this prosecution is grounded in existing federal drug laws, not a new “emergency” power grab. Still, the public will be watching whether the court treats “time served” as acceptable in a case involving a death and alleged continued sales afterward. With sentencing pending, the main unresolved question is how strongly the justice system will deter high-end trafficking networks that market themselves to wealthy or celebrity clientele.